quinazolines has been researched along with Bile Duct Neoplasms in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (26.09) | 29.6817 |
| 2010's | 14 (60.87) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Bachmann, F; Braun, S; Dimova-Dobreva, M; El-Shemerly, M; Engelhardt, M; Forster-Gross, N; Häckl, M; Kellenberger, L; Lane, H; Litherland, K; McKernan, P; McSheehy, P; Polyakova, I; Zhou, P | 1 |
| Mahalapbutr, P; Sawanyawisuth, K; Vaeteewoottacharn, K; Waenphimai, O; Wongkham, S | 1 |
| Javle, M; King, G | 1 |
| Ch'ng, C; Chia, S; Gelmon, K; Ho, C; Ho, J; Ionescu, D; Jones, MR; Jones, SJM; Laskin, J; Leelakumari, S; Lim, H; Ma, Y; Marra, MA; Moore, RA; Mungall, AJ; Mungall, KL; Ng, T; Pleasance, E; Reisle, C; Renouf, DJ; Schaeffer, DF; Shen, Y; Yip, S; Zhao, C; Zhao, Y; Zhong, E | 1 |
| Gourd, E | 1 |
| Feng, J; Geng, R; Jin, Y; Liu, Y; Sun, J; Wei, Y; Zhao, F; Zhao, L; Zhu, B | 1 |
| Abbadessa, G; Alpini, G; Banales, JM; Bhoori, S; Correnti, M; Destro, A; Di Tommaso, L; Droz Dit Busset, M; Elvevi, A; Fiaccadori, K; Forti, E; Gerussi, A; Glaser, S; Hall, T; Invernizzi, P; Marra, F; Mazzaferro, V; Meng, F; Navari, N; Olaizola, P; Pastore, M; Peraldo-Neia, C; Piombanti, B; Raggi, C; Roncalli, M; Rovida, E | 1 |
| Aoudjehane, L; Clapéron, A; Conti, F; Desbois-Mouthon, C; Firrincieli, D; Fouassier, L; Ho-Bouldoires, TH; Housset, C; Merabtene, F; Mergey, M; Prignon, A; Scatton, O; Wendum, D | 1 |
| He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Blanke, CD; El-Khoueiry, AB; Gong, IY; Iqbal, S; Kayaleh, OR; Lenz, HJ; Micetich, KC; Rankin, C; Siegel, AB | 1 |
| Adkins, J; Aldrich, J; Asmann, Y; Baker, A; Barr Fritcher, EG; Barrett, MT; Bhavsar, JD; Bible, KC; Block, M; Borad, MJ; Bryce, AH; Carpten, JD; Champion, MD; Cherni, I; Christoforides, A; Collins, JM; Condjella, RM; Craig, DW; Egan, JB; Fonseca, R; Han, H; Harris, P; Hunt, K; Izatt, T; Kipp, BR; Klee, EW; Kocher, JP; Kurdoglu, A; Lazaridis, KN; Liang, WS; Lobello, J; Mastrian, SD; McCullough, AE; McDonald, J; McWilliams, RR; Middha, S; Nair, AA; Nasser, S; Oliver, GR; Patel, MD; Phillips, L; Placek, P; Reiman, R; Schahl, K; Silva, AC; Stewart, AK; Von Hoff, D; Watanabe, AT; Young, SW | 1 |
| Bahra, M; Boas-Knoop, S; Bova, R; Bradtmöller, M; Guse, K; Kamphues, C; Koch, A; Lippert, S; Neuhaus, P; Riedlinger, D; Sauer, IM; Seehofer, D | 1 |
| Chang, VH; Chen, CC; Jiang, X; Lin, HY; Liu, YR; Wang, J; Yang, SH; Yen, Y; Zhang, K | 1 |
| Hirohashi, S; Kasai, S; Kokubu, A; Ochiya, T; Ojima, H; Shibata, T; Yoshikawa, D | 1 |
| Egawa, S; Katayose, Y; Mizuma, M; Motoi, F; Oda, A; Ohtuska, H; Oikawa, M; Onogawa, T; Rikiyama, T; Sasaki, T; Shirasou, S; Unno, M; Yabuuchi, S; Yamamoto, K; Yoshida, H | 1 |
| Almenara, JA; Campbell, DJ; Dewitt, JL; Oyesanya, RA; Sirica, AE; Zhang, Z | 1 |
| Andersen, JB; Avital, I; Barbour, A; Blechacz, BR; Conner, EA; Factor, VM; Gillen, MC; Komuta, M; Roberts, LR; Roskams, T; Spee, B; Thorgeirsson, SS | 1 |
| Faris, JE; Zhu, AX | 1 |
| Horiguchi, N; Kakizaki, S; Mori, M; Nakajima, Y; Sato, K; Sunaga, N; Takagi, H | 1 |
| Bronk, SF; Gores, GJ; Gwak, GY; Lee, HS; Werneburg, NW; Yoon, JH | 1 |
| Chayama, K; Kuwahara, K; Miyata, H; Sasaki, T; Serikawa, M | 1 |
| Altiok, S; Amador, ML; Chan, A; Hidalgo, M; Jimeno, A; Maitra, A; Mezzadra, H; Nielsen, ME; Patel, P | 1 |
| Dipetrillo, T; Evans, D; Gutman, N; Joseph, P; Kennedy, T; McNulty, B; Millis, R; Miner, T; Plette, A; Resnick, M; Safran, H; Sears, D | 1 |
5 review(s) available for quinazolines and Bile Duct Neoplasms
| Article | Year |
|---|---|
Derazantinib: an investigational drug for the treatment of cholangiocarcinoma.
Topics: Aniline Compounds; Animals; Bile Duct Neoplasms; Cholangiocarcinoma; Drugs, Investigational; Gene Rearrangement; Humans; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2 | 2021 |
FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
Topics: Aniline Compounds; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Clinical Trials as Topic; Humans; Morpholines; Mutation; Phenylurea Compounds; Precision Medicine; Pyrazoles; Pyrimidines; Pyrroles; Quinazolines; Quinoxalines; Receptors, Fibroblast Growth Factor; Signal Transduction | 2021 |
Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors | 2013 |
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Belgium; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chi-Square Distribution; Cholangiocarcinoma; Cluster Analysis; ErbB Receptors; Female; Gene Expression Profiling; Genetic Predisposition to Disease; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lapatinib; Laser Capture Microdissection; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Oligonucleotide Array Sequence Analysis; Patient Selection; Phenotype; Precision Medicine; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Queensland; Quinazolines; ras Proteins; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Trastuzumab; Tumor Microenvironment; United States | 2012 |
Targeted therapy for biliary tract cancers.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cetuximab; Cholangiocarcinoma; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Gallbladder Neoplasms; Humans; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Niacinamide; Panitumumab; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Quinazolines; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome | 2012 |
2 trial(s) available for quinazolines and Bile Duct Neoplasms
| Article | Year |
|---|---|
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Humans; Male; MAP Kinase Signaling System; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Treatment Failure; Vascular Endothelial Growth Factor A | 2014 |
Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Quinazolines; Survival Analysis | 2008 |
16 other study(ies) available for quinazolines and Bile Duct Neoplasms
| Article | Year |
|---|---|
Multiple actions of NMS-P715, the monopolar spindle 1 (MPS1) mitotic checkpoint inhibitor in liver fluke-associated cholangiocarcinoma cells.
Topics: Animals; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Fasciola hepatica; G2 Phase Cell Cycle Checkpoints; Humans; M Phase Cell Cycle Checkpoints; Molecular Docking Simulation; Protein Serine-Threonine Kinases; Pyrazoles; Quinazolines | 2022 |
Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Bile Duct Neoplasms; Cholangiocarcinoma; Female; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Neuregulin-1; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Quinazolines; Syndecan-4 | 2017 |
Derazantinib for intrahepatic cholangiocarcinoma.
Topics: Aniline Compounds; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Gene Fusion; Humans; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2 | 2019 |
Induction of phosphatase shatterproof 2 by evodiamine suppresses the proliferation and invasion of human cholangiocarcinoma.
Topics: Animals; Antineoplastic Agents; Bile Duct Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Enzyme Induction; Humans; Interleukin-6; Mice; Neoplasm Invasiveness; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2019 |
Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma.
Topics: Aniline Compounds; Bile Duct Neoplasms; Cell Proliferation; Cholangiocarcinoma; Epithelial-Mesenchymal Transition; Humans; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Tumor Cells, Cultured | 2019 |
Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor.
Topics: Animals; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Disease Progression; ErbB Receptors; Gefitinib; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms; Mice; Myofibroblasts; Quinazolines; Signal Transduction; Stromal Cells | 2013 |
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Genome, Human; Humans; Imidazoles; Indazoles; Molecular Targeted Therapy; Mutation; Prognosis; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Sulfonamides; Transcriptome | 2014 |
Hedgehog pathway as a potential treatment target in human cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Benzamides; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cells, Cultured; Cholangiocarcinoma; Female; Gene Expression; Gentamicins; Hedgehog Proteins; Heterografts; Humans; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Oncogene Proteins; Patched Receptors; Polymerase Chain Reaction; Quinazolines; Receptors, Cell Surface; RNA, Messenger; Signal Transduction; Trans-Activators; Veratrum Alkaloids; Zinc Finger Protein GLI1 | 2014 |
Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Lung Neoplasms; Male; Mice; Mice, Inbred ICR; Protein Serine-Threonine Kinases; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2015 |
Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma.
Topics: Animals; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Division; Cell Line, Tumor; Cholangiocarcinoma; ErbB Receptors; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Japan; Mice; Mice, Inbred BALB C; Mice, Nude; Piperidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
ZD1839 (IRESSA) stabilizes p27Kip1 and enhances radiosensitivity in cholangiocarcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Cell Cycle; Cell Proliferation; Cholangiocarcinoma; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Quinazolines; Radiation Tolerance; Tumor Cells, Cultured; X-Rays | 2009 |
Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Disease Models, Animal; ErbB Receptors; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Rats; Receptor, ErbB-2; Signal Transduction; Tyrphostins | 2010 |
Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Hep G2 Cells; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Cyclooxygenase 2; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Membrane Proteins; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Quinazolines; Signal Transduction; Tyrphostins; Ubiquitin | 2004 |
The effects of ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor, as a radiosensitiser in bile duct carcinoma cell lines.
Topics: Anthracenes; Bile Duct Neoplasms; Butadienes; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Clone Cells; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; Morpholines; Nitriles; Oncogene Protein v-akt; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Quinazolines; Radiation-Sensitizing Agents | 2006 |
Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration.
Topics: Animals; Antineoplastic Agents; Benzamides; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biopsy, Fine-Needle; Cholangiocarcinoma; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Quinazolines; Signal Transduction | 2006 |